April 12, 2018
Sponsored by
PerkinElmer

Applications and Challenges of Using ctDNA as Non-Invasive Tumor Markers

GenomeWebinar

Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Liquid biopsies are becoming increasingly important for the detection of actionable mutations in cancer due to tumor heterogeneity as well as the practical limitations of invasive tissue biopsies. Recent technological developments enable the use of circulating tumor DNA (ctDNA) as cancer biomarkers as a non-invasive complement and potentially even substitute for tissue biopsies.

Sponsored by

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.